Annovis Bio, Inc. (ANVS) compared with its closest peers (DWTX, VRCA, CING, ELTX, LNAI). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | $83.62M | -0.6 |
| Verrica Pharmaceuticals Inc. (VRCA) | $83.15M | -5.0 |
| Cingulate Inc. (CING) | $80.49M | -1.0 |
| Elicio Therapeutics, Inc. (ELTX) | $79.63M | -3.1 |
| Lunai Bioworks Inc. (LNAI) | $78.35M | — |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO) | $77.03M | -4.0 |
| Serina Therapeutics, Inc. (SER) | $72.65M | -1.0 |
| iBio, Inc. (IBIO) | $71.54M | -0.4 |
| Pliant Therapeutics, Inc. (PLRX) | $71.52M | -0.5 |
| Rein Therapeutics Inc. (RNTX) | $71.52M | -0.6 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
ANVS overview · ANVS earnings · ANVS financials · ANVS KPIs · ANVS investor relations · ANVS ownership · ANVS filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.